Table 3.
Effects of functionally enhanced MSCs in the treatment of kidney disease.
| Pathological Condition | Type of Source | Findings | Reference |
|---|---|---|---|
| Renal IRI | 14S,21R-dHDHA | Enhancement of MSC function, reduction of apoptosis and inflammatory response, improvement of renal function | [90] |
| Renal IRI | SNP | Cyto-protective and tissue-protective effects, promotion of MSC functionality (proliferation, survival) | [91] |
| Renal IRI | DPO | Protective and hematopoietic effects, reduction in kidney damage | [92] |
| Renal IRI | Ator | Improvement of renal function and survival of engrafted MSCs | [93] |
| Ischemic disease with CKD | Melatonin | Reduction in oxidative stress and senescence, increase in angiogenesis and injected MSC survival | [97] |
| CKD | Fucoidan | Inhibition of MSC senescence, increased cell proliferation, enhancement of immunomodulatory activity, recovery of damaged zone | [99] |
| AKI | chitosan-based hydrogel | Enhancement of transplanted MSC retention and survival, protection of MSC from oxidative stress, reduction of apoptosis | [103] |